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ABSTRACT
OBJECTIVE: The Objective of this selective EBM review is to determine where or not, “Is
Incidence of Nausea Influenced by Brintellix (Vortioxetine) in Patients over the Age of 18 with
Major Depressive Disorder (MDD)?”
STUDY DESIGN: Review of three English language primary studies, published between 2011
and 2013
DATA SOUCES: Three double blind randomized controlled trials (RCTs). Sources were found
on PubMed and Cochrane Library databases.
OUTCOMES MEASURED: To measure the incidence of nausea in patients over 18 who are
diagnosed with major depressive disorder taking Brintellix compared to a placebo.
RESULTS: The randomized controlled studies results found that Brintellix was found to
increase incidence of nausea when compared to placebo.
CONCLUSION: Brintellix treatment was well tolerated in patients 18 years and older with major
depressive disorder; with nausea being the most common adverse event reported from patients.
KEY WORDS: Brintellix, nausea, major depressive disorder
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Introduction
Major Depressive Disorders (MDD) is a serious condition that may manifest itself in a
variety of ways. According to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM5), MDD is characterized by five or more symptoms that have been present for the same two
week period and at least one of the symptoms has to be depressed mood or anhedonia.1 The
other presenting symptoms may be significant weight loss or weight gain (>5% of body weight
per month), insomnia or hypersomnia, psychomotor agitation, fatigue or loss of energy, feelings
of worthlessness or excessive guilt, decreased concentration or indecisive, and recurrent thoughts
of death or suicidal ideation.1 These symptoms also have to cause impairment in social or
occupational areas and cannot be attributed to drugs (medical or street), bereavement, or not
better explained by other psychotic disorders.1,7,8,9
Major depression is a common condition affects approximately 14.8 million or 6.7% of
the American population.2 An estimated 121 million people worldwide are currently affected by
a form of depression and MDD is the 4th leading cause of disability worldwide.2 In the United
States, the annual cost related to MDD in 2010 was $210.5 billion dollars.3 The latest statistics
show in 2007-2010 there were 8 million visits per year for major depressive disorder.4 There is a
higher incidence in women than men and MDD is a common comorbidity in patients with
chronic medical conditions (arthritis, DM, heart disease, etc.).5 Major depression may affect all
ages, races, and the incidence increases with age for both genders.5 The etiology for MDD is
thought to be multifactorial, arising from genetic factors (neurotransmitter dysfunction),
developmental (personality issues, childhood events), and psychosocial stress (divorce,
unemployment, etc.).5 Some of the major neurotransmitter contributors to MDD are thought to
be serotonin (5-HT), epinephrine, norepinephrine, and dopamine.5,7,8,9 This is why the
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medications that are given to treat MDD attempt to achieve balance amongst the
neurotransmitters that regulate our overall mood.
Psychotherapy is recommended for patients who suffer from major depressive disorder.
This is a key component to treatment because it allows for a continuous assessment of suicide
risk in this population.5 Psychotherapy is also aided with pharmacotherapy treatment. The drugs
used pharmacotherapy treatment usually takes 3-6 week before the patient notices a positive
affect from the medications.5 The first line treatment in patients with MDD are selective
serotonin reuptake inhibitors (SSRIs), followed by selective norepinephrine reuptake inhibitors
(SNRIs), or other drug classes that may alter brain neurotransmitter activity.5 If patients fail
pharmacological therapy they may be candidates for electroconvulsive therapy or phototherapy. 5
The pharmacological treatments listed above all play an important part in management
for MDD however; these medications may not be tolerated or therapeutic to all patients. The
U.S. Food and Drug Administration (FDA) approved Brintellix in 2013 for the management of
major depressive disorder.6 Brintellix is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5HT1B receptor partial agonist, 5-HT1A receptor agonist and an inhibitor of the 5-HT
transporters.7,8,9 The areas of the brain that Brintellix affects is designed to enhance
neurotransmitter activity, which results in antidepressant activity. Since this drug works in the
central nervous system (CNS) it is important to examine if patients are able to tolerate the CNS
adverse effects associated with Brintellix. The RCT’s demonstrated that there is increased CNS
side effects, most common being nausea, but majority of patients are able to tolerate the
medication and follow through with management.7,8,9
Objective
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The Incidence of nausea is influenced by Brintellix in patients over the age of 18 with
Major Depressive Disorder (MDD).
Method
The criteria used for the 3 RCT studies included patients over 18, diagnosed with MDD,
who met the baseline total score on Montgomery-Asberg Depression Rating Scale (MADRS) on the
first visit. Patients who were eligible for the study were randomized equally to one of the treatment
groups and were instructed to take their medication at the same time each day. The placebo capsule was
identical to Brintellix capsule. Some variations did exist between the three studies. In the study by
Alverez et al. 5mg Brintellix was compared to placebo for six weeks.7 in the study by Boulenger et al.
5mg Brintellix was compared to placebo for eight weeks.8 In the trial by Mahableshwarkar et al. 15mg
Brintellix was compared to placebo for eight weeks.9 The outcomes measured in the three studies
included the incidence of nausea in patients who are taking Brintellix for MDD.
Clinical experts who received rater training and received their rating training certificated were
allowed to rate patients.7,8,9 These experts followed up with the eligible patients to examine the efficacy
and tolerability of the medication. When patients reported to the clinical experts, the patients were asked
non-leading questions, such as, “how do you feel”? All adverse events were either observed by the
clinical expert or reported directly by the patient.
A detailed search using Cochrane Systematic Reviews and PubMed databases were completed by
using the keywords “Vortioxetine”, Major Depression, “Brintellix” with English language being used in
all studies. The three RCTs were published between 2011 -2013 and located in PubMed database.
Articles were selected based on their relevance to clinical practice and importance to patient-oriented
outcomes. Inclusion criteria consisted of articles that were either RCTs or Primary studies which were up
to date with no other systematic review, meta-analysis, or review article found on the Cochrane database
answering the same questions. Studies excluded were those with patients treated with other
antidepressant drugs, current psychiatric disorder other than MDD, current or past history of manic or
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hypomanic episodes, schizophrenia, or any other psychotic features, or received electroconvulsive therapy
within the last six months. A summary of statistics reported or used were CEA, EER, RRI, ARI, NNH,
and P-values. Table 1 displays the demographics and characteristics of these articles.

Table 1 – Demographics & Characteristics of included studies
Study

Type

# Pts

Alvarez7
(2011)

RCT

213

Age
(yrs)
18-65

Boulenger8
(2013)

RCT

151

18-75

Mahableshwarkar9
(2013)

RCT

153

18-75

Inclusion
Criteria
Patients with
MDD presenting
with current
major depressive
episodes
according to
DSM-IV-TR
criteria were
included if there
were an
outpatient of
either sex,
MADRS total
score >30
Primary
diagnosis of
MDD according
to DSM-IV-TR
criteria, a current
major depressive
episode (MDE)
of greater than 3
month’s duration
with a MADRS
score of ≥ 26.

Primary
diagnosis of
major depressive
disorder
(according to
DSM-IV-TR for
at least 3 months
who scores ≥ 22
on MADRS.

Exclusion
Criteria
Current
psychiatric
disorder other
than MDD,
Current or past
history of
manic or
hypomanic
episodes,
schizophrenia,
or any other
psychotic
features

W/D

Interventions

28

Brintellix 5 mg
VS. Placebo
assessing adverse
reactions at each
visit for 6 weeks,
starting at
baseline. During
visits patients
were asked nonleading questions.

Current
psychiatric
disorder other
than MDD as
defined by
DSM-IV-TR or
a current or past
history of a
manic or
hypomanic
episode,
schizophrenia
or any other
psychotic
features
History of
psychosis,
substance
abuse,
neurological
disorders, on a
medication, risk
of suicide,
resistant to 2
adequate antidepressant

34

Brintellix 15 mg
VS. Placebo
assessing adverse
reactions at each
visit for 8 weeks,
starting at
baseline. During
visits patients
were asked nonleading questions.

31

Brintellix 5mg
VS placebo
assessing adverse
reactions at the
end of 8 week
trial, comparing
to baseline.
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treatments for
at least 6 weeks
or received
electroconvulsive
therapy within
6 months

Outcome Measured
The outcomes measured were patient oriented evidence that matters (POEMs), relating to
increased incidence of nausea in patients taking Brintellix for MDD. The patients in the study
had to meet with the clinical expert as scheduled times. During this time the clinical expert
asked non-leading questions such as, how do you feel?7,8,9 Nausea was reported by the patient or
observed by the clinical expert then added to adverse events and analyzed by using the Fischer
exact test.
Results
The three studies chosen evaluated for the incidence of nausea in patients 18 and older
taking Brintellix for MDD.7,8,9 All patients included in each study were assessed prior to
eligibility and assessed through the study at prescribed intervals. All the studies compared
Brintellix to a placebo group, but varied in duration of study or dosage of Brintellix given.
During the duration of the study adverse events were recorded, with nausea being the most
common adverse event.7,8,9
In the study conducted by Alvarez et al.7 (2011) analyzed if the incidence of nausea is
increased in patients taking 5mg of Brintellix (n=108; 38 male 70 female) compared to the
placebo (n=105; 36 male 69 female). The study design was a randomized, double blind, placebo
controlled trial for a six week duration. In the experimental and control there were male/female
18 years and older with a diagnosis of MDD. Refer to Table 1 for inclusion and exclusion
criteria. Incidence of nausea was assessed after the completion of each week until the study was
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finished. After the completion of the study patients were tapered off for two weeks. The
experimental and control group both received the placebo for two weeks and then reported for a
safety follow-up 4 weeks after the completion of the study. It was reported that 18 (4 to adverse
events) patients withdrew from the control group and 10 (3 to adverse events) patients withdrew
from the experimental group. Patient withdrawal in either group due to nausea was 0. 10 (9.5%)
patients in the control group and 32 (29.6%) patients in the experiential group reported nausea.
Patients taking 5mg of Brintellix had a 2.12 times higher risk of experiencing nausea as those
taking control. Patients taking 5mg of Brintellix had a 20.1% absolute increase in experiencing
nausea. For every 4 MDD patients taking 5mg Brintellix, 1 patient would also experience
nausea, compared to control. At the end of the study there was a significant (p<0.001) increase
in nausea in experimental group compared to control group (Table 2).
In the study conducted by Boulenger et al8 (2013) analyzed if the incidence of nausea is
increased in patients taking 15mg of Brintellix (n=151; 54 male 97 female) compared to the
placebo (n=158; 48 male 110 female). The study design was a randomized, double blind,
placebo controlled trial for 8 weeks. In the experimental and control group there were
male/female 18 years and older with a diagnosis of MDD. Refer to Table 1 for inclusion and
exclusion criteria. Incidence of nausea was assessed weekly for the first 2 weeks and then every
2 weeks till the end of the study. After the completion of the study, experimental and control
were tapered off for 2 weeks with placebo and followed up on 4th week for safety measures. It
was reported that 25 (7 to adverse events) patients withdrew from control group and 34 (10 to
adverse events) patients withdrew from experimental group. The leading adverse event that
leads for withdrawal was nausea in the experimental group. The study did not specify the
leading cause of withdrawal in control group. 16 (10.1%) patients in the control group and 40
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(26.5%) in the experimental group reported nausea. Patients taking 15mg of Brintellix had a
2.15 higher risk of experiencing nausea as those taking control. Patients taking 15 mg of
Brintellix had a 21.7% absolute increase in experiencing nausea. For every 4 MDD patients
taking 15mg Brintellix, 1 additional patient would also experience nausea, compared to control.
At the end of the study there was a significant (p<0.001) increase in nausea in experimental
group compared to control group (Table 2).
In the study conducted by Mahableshwarkar et al.9 (2011) analyzed if the incidence of
nausea is increased in patients taking 5mg of Brintellix (n=122; 60 male/93 female) compared to
the placebo group (n=120; 47 male/106 female). The study design was a randomized, double
blind, placebo controlled trial for 8 weeks. In the experimental and control group there were
male and female 18 years and older with a diagnosis of MDD. Refer to Table 1 for inclusion and
exclusion criteria. Incidence of nausea was assessed at weeks 1,2,4,6, and 8. Control and
experimental group were both given a placebo taper for 1 week following the study. Safety
follow up was done over the phone, 4 weeks after the study. It was reported that 33 (7 to adverse
events) participants withdrew from the placebo group and 31 (12 to adverse events) withdrew
from experiential group. The study did not specify if adverse events relating to nausea was a
cause of withdraw. 16 (10.6%) patients in the control group and 44 patients in the experimental
group reported nausea. Patients taking 5mg of Brintellix had a 1.72 higher risk of experiencing
nausea as those taking control. Patients taking 5mg of Brintellix had an 18.2% absolute increase
in experiencing nausea. For every 5 MDD patients 18 years and older taking 5mg Brintellix, 1
additional patient would also experience nausea, compared to control. At the end of the study
there was a significant (p<0.05) increase in nausea in experimental group compared to control
group (Table 2).
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Table 2 - Incidence of Nausea is Influenced by Brintellix (Vortioxetine) in Patients Over the
Age of 18 with Major Depressive Disorder (MDD)
Study

Control
event
rate
(CER)
Alvarez et al.7
9.5%
Boulenger et al.8 10.1%
Mahableshwarkar 10.6%
et al.9

Experimental
event rate
(EER)
Dosage/ EER
5mg/29.6%
15mg/31.8%
5mg/28.8%

Relative Absolute Number P-value Statistically
risk
risk
needed
Significant
increase increase to harm
(RRI)
(ARI)
(NNH)
212%
20.1%
4
P<0.001
Yes
215%
21.7%
4
P<0.001
Yes
172%
18.2%
5
P<0.05
Yes

Discussion
Major Depressive Disorder is a serious condition that may manifest itself in a variety of
ways. Treatment for MDD is difficult due to the fact that a variety of variables contribute to this
condition. Using pharmacological therapy to attempt to balance the CNS neurotransmitters has
been shown to be an effective treatment for MDD. When choosing a medication for any
condition it is important to weigh the advantages vs the disadvantages of a medication. For
example, a medication may be effective for desired outcome but the adverse effect(s) of the
medication may also be harmful. Therefore it is important for a patient to pick a medication that
is effective and tolerable than a medication that will treat a symptom but replace it with another.
These decisions are even more important for patients who have to take a medication for the rest
of their life.
Brintellix is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial
agonist, 5-HT1A receptor agonist and an inhibitor of the 5-HT transporters.7,8,9 Brintellix was
approved for the treatment of MDD on September 30, 2013 and is considered a multimodal
antidepressant because it works in multiple ways in the CNS.6 Brintellix is available in 5mg, 10
mg, 15mg, and 20mg tablets and cost for 1 month supply ranges from $300-350$.10 However,
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with the availability of cost reduction cards and insurance, many patients pay $50-$100 per
month.11 This medication is used to treat major depressive disorder and has a black box warning
with increased suicide in children, young adults, and adults > 65 years old. The only indication
for the use of Brintellix is major depressive disorder. 6,10
Patients with MDD are known to have a high relapse rate and often are found taking
antidepressants for the duration of their life.5 The three RCTs found that Brintellix was an
effective treatment for MDD in patients over 18 years old but the focus of this study was to
analyze the impact of nausea due to Brintellix therapy.7,8,9 Nausea was reported as the most
common adverse event during the trails.7,8,9 Even though nausea was the number one adverse
event the studies reported that they were mild cases.7,8,9 So the severity of nausea was low.
Therefore, even though Brintellix was significant for increasing incidence of nausea, due to the
low severity of nausea, Brintellix was well tolerated by the patients.
Similar limitations existed in all the following studies. In the three RCTs nausea was
reported by participant or observed by the clinical expert during follow up. Nausea is a symptom
that may arise from a variety of reasons such as, diet, exercise, emotional stress, motion sickness,
etc. Therefore it may be difficult to decipher if nausea was contributed by lifestyle factors or
primarily from the experimental arm. The study did not include this variable as a possibility
which would result in false positives. Due to this limitation, there needs to be a more valid
procedure in recording the influence of nausea due to Brintellix.
Conclusion
The systematic review of three randomized controlled trails comparing Brintellix to a
control group concluded that Brintellix was influential in increasing the incidence of nausea in
patients over 18 with major depressive disorder. Variability of major depressive disorder
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medications is important because these mediations affect the CNS which may contribute to
undesirable adverse reactions. With more pharmacological options available helps increases the
opportunity for management of MDD. Future studies should include extra guideline with
reporting incidence of nausea, allowing for clinical reporters to decipher if nausea is due to
lifestyle factors or Brintellix.
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